J Drugs Dermatol
-
Multicenter Study Clinical Trial
An open-label, pilot study to assess the effectiveness and safety of hyaluronic acid gel in the restoration of soft tissue fullness of the lips.
There have been few systematic investigations of the effectiveness, safety and tolerability of aesthetic lip augmentation using hyaluronic acid (HA) fillers. ⋯ Lip augmentation with SGP-HA was well tolerated and resulted in clinically meaningful increases in lip fullness.
-
Herpes zoster is a skin disease encountered commonly in dermatologic practice. While post-herpetic neuralgia (PHN) is a familiar side effect of this condition, it is not the only neuropathic symptom that can result. ⋯ Gabapentin has been successfully used to treat cutaneous pain and pruritus in a variety of conditions. The authors describe a case of PHI successfully treated with a course of gabapentin and propose that this agent be considered for use in patients who present with PHI.
-
Clinical Trial
Safety and efficacy of a rapid-acting topical 4% lidocaine gel in a unique drug delivery system.
Ideally, topical anesthetics should provide rapid analgesic action without causing toxic blood levels of lidocaine or other side effects. Various formulations of lidocaine as a topical anesthetic have been tested and are currently on the market. Here, the authors report on a topical lidocaine with a novel delivery system that provides a rapid onset of action without toxic plasma els of lidocaine. ⋯ Topical 4% lidocaine gel with a unique drug delivery system produces significant anesthesia without occlusion in approximately 25-30 minutes with optimal effects observed between 35-40 minutes after application. Topical 4% lidocaine gel can be used effectively and safely as a topical anesthetic in the physician's office.
-
Randomized Controlled Trial
The effect of lidocaine when mixed with large gel particle hyaluronic acid filler tolerability and longevity: a six-month trial.
To determine if there is any effect on tolerance, adverse events or clinical outcome when lidocaine is added to large gel particle hyaluronic acid (LGP-HA). ⋯ This is the first trial to report a six-month follow-up in a split-face study comparing LGP-HA + L to LGP-HA alone. All participant and investigator reports found symmetry of the NLFs at six months, thus demonstrating that the addition of lidocaine to LGP-HA does not affect longevity. Administration of LGP-HA + L is associated with less patient discomfort than administration of LGP-HA alone.
-
Case Reports
Progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab.
Progressive multifocal leukoencephalopathy (PML) is a rare neurological disorder that occurs almost exclusively in immunocompromised individuals by reactivation of the John Cunningham virus (JC virus), a polyomavirus found latent in more than 80 percent of healthy adults. Efalizumab, an immunosuppressive monoclonal antibody targeting T cells, has been used for treatment of moderate-to-severe chronic psoriasis. The authors describe two cases of PML that occurred in patients < or = 70 years old treated with efalizumab for more than three years. ⋯ PML was diagnosed, and the presence of JC virus was confirmed in spinal fluid samples. Both patients died shortly after diagnosis. Dermatologists treating patients with immunosuppressive agents should be alert for the symptoms of PML and seek immediate consultation with a neurologist should symptoms arise.